TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.…
TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
TG Therapeutics (NASDAQ: TGTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 399 employees.
The shares were at 63.34 USD on 20 November 2026, up 90.4% over 52 weeks. Its 52-week range is 26.76 USD to 68.03 USD: the price is 6.9% below the high and 136.7% above the low.
At a market capitalisation of 9.57B USD, it trades at 94.5 times trailing earnings and 24.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 185% for TGTX.
TG Therapeutics reports return on equity of 69.0%, an operating margin of 21.5% and revenue up 60.7% year over year.
Its debt exceeds its cash by 249.70M USD, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 69.43 USD is 9.6% above the current price. The next earnings report is expected on 1 March 2027.